Moderna (NASDAQ:MRNA) President Sells $2,739,870.32 in Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the sale, the president owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. This represents a 3.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

• On Friday, May 15th, Stephen Hoge sold 53,336 shares of Moderna stock. The shares were sold at an average price of $48.40, for a total transaction of $2,581,462.40.

Moderna Price Performance

Shares of MRNA stock opened at $63.96 on Friday. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $67.74. The stock has a market cap of $25.38 billion, a PE ratio of -7.85 and a beta of 1.05. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. The firm’s 50 day moving average price is $50.56 and its two-hundred day moving average price is $45.23.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The business had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.Moderna’s revenue was up 260.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.52) EPS. As a group, analysts forecast that Moderna, Inc. will post -6.51 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a report on Friday, June 12th. Jefferies Financial Group restated a “hold” rating on shares of Moderna in a report on Thursday. Piper Sandler boosted their target price on Moderna from $63.00 to $69.00 and gave the stock an “overweight” rating in a research report on Monday, February 23rd. Barclays upped their price target on Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a research note on Thursday, April 2nd. Finally, Morgan Stanley set a $33.00 price target on shares of Moderna in a research report on Friday, May 1st. Two equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Moderna has an average rating of “Reduce” and a consensus price target of $36.60.

Institutional Trading of Moderna

Hedge funds have recently added to or reduced their stakes in the business. Assetmark Inc. raised its stake in Moderna by 35.1% in the 1st quarter. Assetmark Inc. now owns 801 shares of the company’s stock valued at $41,000 after acquiring an additional 208 shares during the period. New Mexico Educational Retirement Board boosted its position in Moderna by 1.9% during the fourth quarter. New Mexico Educational Retirement Board now owns 15,700 shares of the company’s stock worth $463,000 after purchasing an additional 300 shares during the period. Cromwell Holdings LLC boosted its position in Moderna by 39.7% during the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after purchasing an additional 341 shares during the period. IFP Advisors Inc increased its holdings in shares of Moderna by 5.4% in the fourth quarter. IFP Advisors Inc now owns 6,785 shares of the company’s stock valued at $200,000 after purchasing an additional 348 shares during the last quarter. Finally, Empowered Funds LLC increased its holdings in shares of Moderna by 2.6% in the fourth quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock valued at $405,000 after purchasing an additional 353 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA advisers unanimously backed Moderna’s mRNA flu vaccine, boosting confidence that the shot could win approval and become a new revenue driver if the agency follows the panel’s recommendation. Article: MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing
• Positive Sentiment: Investor sentiment was also helped by reports that Moderna’s shares have been surging on the flu-vaccine catalyst, with some traders positioning for further upside ahead of the FDA’s final ruling. Article: US FDA advisers vote in favor of Moderna’s flu vaccine
• Positive Sentiment: Unusually heavy call-option buying signals that some investors are betting the rally can continue as the FDA review progresses. Article: Moderna, Inc. (NASDAQ:MRNA) – Get Free Report
• Neutral Sentiment: Moderna’s president sold shares under a pre-arranged trading plan, which is worth noting but does not necessarily indicate a change in the company’s outlook. Article: Moderna (NASDAQ:MRNA) President Sells $2,739,870.32 in Stock
• Neutral Sentiment: The stock may stay volatile until the FDA makes its final decision on the flu vaccine by Aug. 5. Article: Moderna’s mRNA flu vaccine faces FDA advisory panel scrutiny

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.